Nasdaq exas.

EXAS has also entered a partnership in mid-2015 with the University of Texas MD Anderson Cancer Center to develop screening and diagnostic tests for lung cancer, the most deadly form of cancer in ...Find the latest analyst research for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...In summary, the author projects Exact Sciences Corporation (NASDAQ: EXAS) as a "buy" at a 1-year price target of $150 (+13% upside) with a strong further upside through 2023.

EXACT Sciences Corporation (NASDAQ:EXAS) Number of Hedge Fund Holders: 28. Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products ...9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...

Who is on Exact Sciences's Insider Roster? The list of insiders at Exact Sciences includes Brian Baranick, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella. Learn more on insiders at EXAS.

Share $67.49 Nov 29, 10:10:29 AM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Apple Inc $191.11 AAPL0.37% Pacific Biosciences of California Inc $8.85 PACB2.55% Amazon.com Inc $147.18... Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.10 +0.07 (+0.10%) After hours: 07:58PM...Exact Sciences Corporation EXAS continues to make significant progress with its Cologuard test. However, the pandemic-led continued business disruption is a concern. Exact Sciences currently ...Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.04. Delayed Data. As of Nov 29. +0.09 / +0.14%. Today’s Change. 40.73. Today ||| 52-Week Range.11 Okt 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...

Exact Sciences Corp (NASDAQ:EXAS), a leading global cancer diagnostics company, has recently released its SEC 10-Q filing for the quarter ended September 30, 2023. The company has shown ...

One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...

MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473 .8 million ...Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ...Oct 8, 2023 · Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ... Fintel reports that on October 10, 2023, Piper Sandler upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Neutral to Overweight. As of October 5, 2023, the average one-year price target ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on ...TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Get the latest Exact Sciences Corporation (EXAS) stock news and headlines to help you in your trading and investing decisions.Exact Sciences Corp (NASDAQ:EXAS) reported a 20% increase in total revenue for Q3 2023, reaching $628 million. The company delivered over a million test results, including a record for Cologuard ...May 11, 2023 · Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ... Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...

Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.20 Okt 2023 ... PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will ...

Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... EXAS earnings call for the period ending March 31, 2023. Image source: The Motley Fool. Exact Sciences ( EXAS 0.14% ) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ET17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...Market Activity Funds + ETFs After-Hours Quotes News + Insights P/E & PEG Ratios Nasdaq MarketSIte Do Not Sell My Personal Information (CA Residents Only) © 2022, …WebSep 6, 2023 · After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ... Exact Sciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 28.7% per year. This section of the company report contains some beta features. How Exact Sciences makes and spends money.First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.In summary, the author projects Exact Sciences Corporation (NASDAQ: EXAS) as a "buy" at a 1-year price target of $150 (+13% upside) with a strong further upside through 2023.

Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...

Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?

TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.View Our Latest Research Report on EXAS. Exact Sciences Price Performance. Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to ...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard ...Find out the direct holders, institutional holders and mutual fund holders for Exact Sciences Corporation (EXAS).Still, here are two companies that could pull it off: Exact Sciences ( EXAS 0.37%) and Airbnb ( ABNB 1.75%). Let's consider why these two innovative businesses could turn $1,000 into $2,000 by the ...Exact Sciences ( EXAS 8.39%) can't claim all the credit, but the non-invasive cancer tests that it markets play an important role. The company's cancer tests screened around 4 million people in ...Exact Sciences (EXAS) closed the most recent trading day at $60.68, moving -0.49% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.77%. Meanwhile, the ...

Exact Sciences world-class team is the driving force behind the most innovative growth engine in cancer diagnostics. Our scientists are using advanced technologies to harness the power of DNA, RNA ...First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...Published. May 23, 2022 11:22AM EDT. Exact Sciences Corporation EXAS is well-poised for growth, backed by impressive first-quarter 2022 results. Further, the company’s legacy Screening business ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Instagram:https://instagram. one battery company stockis charles schwab safenasdaq avgrtop selling beer in america Source: Third-quarter 2023 earnings slides. Currently, EXAS projects its 2023 revenue to be between $2.48 billion and $2.49 billion. Yet, at its current growth pace, my calculations suggest a more ... best short stocks1943 steel penny value today 9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ... quarter that has 1776 and 1976 One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Exact Sciences Corporation Common Stock (EXAS) Nasdaq Listed; ... Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Exact Sciences (NASDAQ: EXAS) may have sunk in recent months. However, the adoption of the company’s Cologuard colon cancer test is growing rapidly, while its multi-cancer blood test looks ...